- Home
- PRTG vs LYRA Comparison
PRTG vs LYRA Comparison
Compare PRTG & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTG
- LYRA
- Stock Information
- Founded
- PRTG 1973
- LYRA 2005
- Country
- PRTG British Virgin Islands
- LYRA United States
- Employees
- PRTG N/A
- LYRA N/A
- Industry
- PRTG Oil & Gas Production
- LYRA Medical/Dental Instruments
- Sector
- PRTG Energy
- LYRA Health Care
- Exchange
- PRTG Nasdaq
- LYRA Nasdaq
- Market Cap
- PRTG 17.7M
- LYRA 15.0M
- IPO Year
- PRTG N/A
- LYRA 2020
- Fundamental
- Price
- PRTG $8.85
- LYRA $6.67
- Analyst Decision
- PRTG
- LYRA Buy
- Analyst Count
- PRTG 0
- LYRA 2
- Target Price
- PRTG N/A
- LYRA $16.00
- AVG Volume (30 Days)
- PRTG 44.3K
- LYRA 29.9K
- Earning Date
- PRTG 08-26-2025
- LYRA 08-18-2025
- Dividend Yield
- PRTG N/A
- LYRA N/A
- EPS Growth
- PRTG N/A
- LYRA N/A
- EPS
- PRTG N/A
- LYRA N/A
- Revenue
- PRTG N/A
- LYRA $1,185,000.00
- Revenue This Year
- PRTG N/A
- LYRA N/A
- Revenue Next Year
- PRTG N/A
- LYRA $139.18
- P/E Ratio
- PRTG N/A
- LYRA N/A
- Revenue Growth
- PRTG N/A
- LYRA N/A
- 52 Week Low
- PRTG $2.10
- LYRA $3.81
- 52 Week High
- PRTG $23.01
- LYRA $37.50
- Technical
- Relative Strength Index (RSI)
- PRTG 65.34
- LYRA 36.02
- Support Level
- PRTG $8.08
- LYRA $6.54
- Resistance Level
- PRTG $10.25
- LYRA $7.10
- Average True Range (ATR)
- PRTG 0.87
- LYRA 0.54
- MACD
- PRTG 0.43
- LYRA 0.03
- Stochastic Oscillator
- PRTG 71.72
- LYRA 14.89
About PRTG Portage Biotech Inc.
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.